DS
OREX

DRW Securities’s Orexigen Therapeutics, Inc. OREX Stock Holding History

DRW Securities’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-6,610
Closed -$327K – 136
2015
Q2 		$327K Sell
6,610
-41,950
-86% -$2.51M 0.04% 84
2015
Q1 		$3.8M Buy
+48,560
New +$3.01M 0.59% 18
2014
Q2 		– Sell
-4,000
Closed -$260K – 197
2014
Q1 		$260K Sell
4,000
-1,500
-27% -$101K 0.02% 94
2013
Q4 		$310K Buy
+5,500
New +$309K 0.01% 148

Other funds holding OREX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

DRW Securities's OREX Position: Q3 2015 in Review

DRW Securities sold out of Orexigen Therapeutics, Inc. (OREX) in Q3 2015, closing a stake of 6,610 shares — an estimated $327K sold.

DRW Securities first reported a position in OREX in Q4 2013 and held it in 4 quarters. The position peaked at $3.8M in Q1 2015. 132 funds tracked by Wall St. Rank hold OREX as of Q3 2015.

  • DRW Securities reported no remaining Orexigen Therapeutics, Inc. position as of Q3 2015 after selling out during the quarter.
  • DRW Securities sold 6,610 Orexigen Therapeutics, Inc. shares in Q3 2015, an estimated $327K.
  • DRW Securities first reported a position in Orexigen Therapeutics, Inc. in Q4 2013 and held it in 4 quarters.
  • DRW Securities's Orexigen Therapeutics, Inc. position peaked at $3.8M in Q1 2015.
  • 132 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2015.

Based on DRW Securities's 13F filing for Q3 2015, filed 16 Nov 2015.